The Grades 3–4 adverse reactions in the non‐inosine group included neutropenia in 11 (13%) patients, platelet decrease in 11 (13%) patients, alanine aminotransferase increased in 4 (5%) patients, and aspartate aminotransferase increase in five (6%) patients. This evidence concerns the gene GPT and neutropenia.